NLG919

SKU: orb1307405

Description

IDO-IN-7 is a potent small molecule inhibitor of indoleamine 2,3-dioxygenase (IDO1), an analogue of NLG-919. It is used in research to investigate the IDO pathway in immunology and oncology, with applications in both in vitro cellular assays and in vivo tumor model studies.

Research Area

Immunology & Inflammation

Key Properties

• CAS Number: 1402836-58-1
• MW: 282.39
• Purity: >98%
• Formula: C₁₈H₂₂N₂O
• SMILES: OC(CC1c2ccccc2-c2cncn12)C1CCCCC1
• Target: Tryptophan
• Solubility: Soluble in DMSO (up to 10 mg/ml)

Bioactivity

• Target IC50:
  IDO:75 nM(EC50)
• In Vivo:
  NLG919 effectively blocks the IDO-induced suppression of T-cell responses, restoring T-cell activity (ED50=80 nM). In mouse dendritic cells (DCs) expressing IDO from tumor lymph nodes (ED50=120 nM), NLG919 abolishes the IDO-induced inhibition of antigen-specific T-cells (OT-1).
• In Vitro:
  In mice bearing B16F10 tumors, NLG919 significantly enhanced the antitumor response of pmel-1 resting cells to homologous hgp100 peptide and CpG-1826.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Indoleamine2,3Dioxygenase(IDO), Indoleamine 2,3-Dioxygenase (IDO), Indoleamine2,3Dioxygenase, Indoleamine 2,3-Dioxygenase, Indoleamine 2,3Dioxygenase (IDO), Navoximod, Navoximod analogue, NLG 919, NLG919, NLG-919, NLG919 analogue, NLG-919 analogue, IDO, IDO IN 7, IDOIN7, IDO-IN-7, GDC 0919, GDC0919, GDC-0919, GDC-0919, GDC-0919 analogue

Compound Identifiers

PubChem CID

66558287